INFLUENCES ON THE ADOPTION OF NEW PHARMACEUTICAL TECHNOLOGIES: THE EXAMPLE OF THE FENTANYL PATCH
ABSTRACT Little documentation exists in the scientific literature on the introduction of new technologies in health care, especially for pharmaceuticals. Few adequate databases are available to be mined, and the methodologies are often outmoded. Thus, the past literature may be incomplete or mislead...
Saved in:
Published in | Clinical research and regulatory affairs Vol. 19; no. 4; pp. 397 - 412 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Informa UK Ltd
2002
Taylor & Francis |
Online Access | Get full text |
Cover
Loading…
Abstract | ABSTRACT
Little documentation exists in the scientific literature on the introduction of new technologies in health care, especially for pharmaceuticals. Few adequate databases are available to be mined, and the methodologies are often outmoded. Thus, the past literature may be incomplete or misleading since important changes have occurred in the pharmaceutical industry and in its marketing strategies over the last decade. These changes include the advent of direct-to-consumer advertising, the lessening of reliance upon professional journal ads, the expansion of the ranks of manufacturers' detail representatives, and use of "value-added" inducements to large purchasing groups.
A study utilizing the triplicate prescription control program data was analyzed with the Bass model, from the field of marketing, to examine as an example of a new pharmaceutical diffusion, the fentanyl patch. Estimates of the relative importance of the interpersonal influence and the external influences (e.g., mass media advertisement) on prescribing indicated that, unlike traditional diffusion models that emphasized interpersonal influence, the diffusion of the fentanyl patch in the 1990 s was predominately dependent upon external influence. This approach is useful for firms specifically tailoring marketing strategies to unreached markets. Additionally, from a public health perspective, it may be possible for policy makers to use this methodological approach to identify sub-optimal diffusion and develop interventions accordingly to promote fuller access to care for those in need. |
---|---|
AbstractList | Little documentation exists in the scientific literature on the introduction of new technologies in health care, especially for pharmaceuticals. Few adequate databases are available to be mined, and the methodologies are often outmoded. Thus, the past literature may be incomplete or misleading since important changes have occurred in the pharmaceutical industry and in its marketing strategies over the last decade. These changes include the advent of direct-to-consumer advertising, the lessening of reliance upon professional journal ads, the expansion of the ranks of manufacturers' detail representatives, and use of "value-added" inducements to large purchasing groups.
A study utilizing the triplicate prescription control program data was analyzed with the Bass model, from the field of marketing, to examine as an example of a new pharmaceutical diffusion, the fentanyl patch. Estimates of the relative importance of the interpersonal influence and the external influences (e.g., mass media advertisement) on prescribing indicated that, unlike traditional diffusion models that emphasized interpersonal influence, the diffusion of the fentanyl patch in the 1990 s was predominately dependent upon external influence. This approach is useful for firms specifically tailoring marketing strategies to unreached markets. Additionally, from a public health perspective, it may be possible for policy makers to use this methodological approach to identify sub-optimal diffusion and develop interventions accordingly to promote fuller access to care for those in need. ABSTRACT Little documentation exists in the scientific literature on the introduction of new technologies in health care, especially for pharmaceuticals. Few adequate databases are available to be mined, and the methodologies are often outmoded. Thus, the past literature may be incomplete or misleading since important changes have occurred in the pharmaceutical industry and in its marketing strategies over the last decade. These changes include the advent of direct-to-consumer advertising, the lessening of reliance upon professional journal ads, the expansion of the ranks of manufacturers' detail representatives, and use of "value-added" inducements to large purchasing groups. A study utilizing the triplicate prescription control program data was analyzed with the Bass model, from the field of marketing, to examine as an example of a new pharmaceutical diffusion, the fentanyl patch. Estimates of the relative importance of the interpersonal influence and the external influences (e.g., mass media advertisement) on prescribing indicated that, unlike traditional diffusion models that emphasized interpersonal influence, the diffusion of the fentanyl patch in the 1990 s was predominately dependent upon external influence. This approach is useful for firms specifically tailoring marketing strategies to unreached markets. Additionally, from a public health perspective, it may be possible for policy makers to use this methodological approach to identify sub-optimal diffusion and develop interventions accordingly to promote fuller access to care for those in need. |
Author | Salmon, J. Warren Crawford, Stephanie Y. Lin, Swu-Jane |
Author_xml | – sequence: 1 givenname: J. Warren surname: Salmon fullname: Salmon, J. Warren organization: Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago – sequence: 2 givenname: Swu-Jane surname: Lin fullname: Lin, Swu-Jane organization: Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago – sequence: 3 givenname: Stephanie Y. surname: Crawford fullname: Crawford, Stephanie Y. organization: Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago |
BookMark | eNp1UF1PgzAUbYwmbtNH3_kDaD-AMt8IFiFhQDYW9al2XZttYWDKjNm_tzhj4sPuw_3KOefmnjG4bLtWAXCH4D2CIXqI55WLMIQo8EhwAUbIJ9jFPkaXtocBdBEh5BqM-34HIcQBDUbgPSuSfMmKmC2csnDqlDnRU1nVmR3KxCnYi1Ol0XwWxWxZZ3GUOzWL06LMy-eMLR5_COw1mlU5G_DDmLCijoq33KmiOk5vwJUWTa9uf-sELBNm9-6gYPVcSQg-uNM1WvlKklB50IM2S6KpmkodykBorCUSUPh4rYXQVCsqqF55Hg1s4CnVgkyAe9KVput7ozT_MNu9MEeOIB_s4dYe_mePxYcn_LbVndmLr840a34Qx6Yz2ohWbntOzlHpP-pGieawkcIovus-TWvfPHP0G1iOdoc |
CitedBy_id | crossref_primary_10_1016_j_clinthera_2007_02_017 |
Cites_doi | 10.2165/00019053-199303050-00003 10.1016/S0277-9536(97)00108-1 10.2307/3172552 10.2165/00019053-199915050-00004 10.1287/mnsc.33.9.1069 10.7326/0003-4819-119-2-199307150-00005 10.1056/NEJM198611133152005 10.1016/S0360-3016(99)00276-X 10.1056/NEJM198811033191810 10.18553/jmcp.2001.7.4.272 10.1287/mnsc.15.5.215 10.1038/scientificamerican0482-120 10.1080/02791072.1991.10471602 10.1056/NEJMsa012075 10.1016/0002-9343(82)90911-1 |
ContentType | Journal Article |
Copyright | 2002 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2002 |
Copyright_xml | – notice: 2002 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2002 |
DBID | AAYXX CITATION |
DOI | 10.1081/CRP-120016436 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1532-2521 |
EndPage | 412 |
ExternalDocumentID | 10_1081_CRP_120016436 11178886 |
Genre | Research Article |
GroupedDBID | --- 00X 0R~ 29B 4.4 53G 5GY 5VS AALIY AAPXX ABDBF ABJNI ABWCV ABZEW ACGEJ ACGFS ACKZS ADCVX ADFOM ADFZZ ADXPE AEIIZ AFKVX AFLEI AJVHN AJWEG ALMA_UNASSIGNED_HOLDINGS AWYRJ BABNJ BLEHA BRMBE CAG COF CS3 CYYVM CZDIS DRXRE DWTOO EAP EBD EBO EBS EJD EMK EPL ESX F5P H13 HZ~ JENTW KRBQP KWAYT M44 M4Z MK0 NUSFT O9- P2P QQXMO TDBHL TFDNU TFL TFW TH9 TUS V1S ZGI ~1N AEYQI ALIIL AAORF AAYXX CITATION |
ID | FETCH-LOGICAL-c332t-9d1b5ec38e40408e4c3f7e9cf8c6af2fc1a0a52dfaaf7fe7a7fb4476666297fa3 |
ISSN | 1060-1333 |
IngestDate | Thu Sep 26 18:35:08 EDT 2024 Wed Mar 06 05:02:04 EST 2024 Tue Sep 17 11:17:35 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c332t-9d1b5ec38e40408e4c3f7e9cf8c6af2fc1a0a52dfaaf7fe7a7fb4476666297fa3 |
PageCount | 16 |
ParticipantIDs | informaworld_taylorfrancis_310_1081_CRP_120016436 informahealthcare_journals_10_1081_CRP_120016436 crossref_primary_10_1081_CRP_120016436 |
PublicationCentury | 2000 |
PublicationDate | 20020000 1/1/2002 2002-01-00 |
PublicationDateYYYYMMDD | 2002-01-01 |
PublicationDate_xml | – year: 2002 text: 20020000 |
PublicationDecade | 2000 |
PublicationTitle | Clinical research and regulatory affairs |
PublicationYear | 2002 |
Publisher | Informa UK Ltd Taylor & Francis |
Publisher_xml | – name: Informa UK Ltd – name: Taylor & Francis |
References | Freudenheim M (CIT0003) 2002 Williams J.R. (CIT0007) 1991; 11 Coleman J.S. (CIT0028) 1966 CIT0030 CIT0032 CIT0034 CIT0011 Salmon J (CIT0015) 1996 Johnson J. (CIT0021) 1994; 51 Lin S. (CIT0025) 2002 Kongstvedt P (CIT0029) 1999 Langley P (CIT0016) 1993; 15 CIT0036 CIT0038 CIT0037 CIT0018 CIT0017 Fuchs V (CIT0001) 1972 CIT0041 CIT0040 Bennett J (CIT0010) 2002 Singer I (CIT0002) 2001 Thompson A.R. (CIT0039) 1999; 14 Data J.L. (CIT0020) 1995; 31 Borzo G (CIT0023) 1997; 1 Rogers E.M (CIT0005) 1983 Martinez B (CIT0009) 2002 Salmon J (CIT0031) 1994 CIT0024 Rosenbaum D.E (CIT0004) 2002 Hensley S (CIT0012) 2002 Visawanathan H. (CIT0014) 2000; 6 CIT0026 CIT0006 CIT0008 Sullivan S. (CIT0019) 2001; 7 |
References_xml | – volume: 6 start-page: 1117 year: 2000 ident: CIT0014 publication-title: American Journal of Managed Care contributor: fullname: Visawanathan H. – ident: CIT0017 doi: 10.2165/00019053-199303050-00003 – year: 2002 ident: CIT0004 publication-title: New York Times contributor: fullname: Rosenbaum D.E – ident: CIT0024 doi: 10.1016/S0277-9536(97)00108-1 – volume-title: Diffusion of Innovations year: 1983 ident: CIT0005 contributor: fullname: Rogers E.M – ident: CIT0026 doi: 10.2307/3172552 – ident: CIT0018 doi: 10.2165/00019053-199915050-00004 – ident: CIT0030 doi: 10.1287/mnsc.33.9.1069 – volume-title: The Corporate Transformation of Health Care, Part II: Perspectives and Implication year: 1994 ident: CIT0031 contributor: fullname: Salmon J – volume-title: The State of Health Care in America, 2001 year: 2001 ident: CIT0002 contributor: fullname: Singer I – ident: CIT0040 doi: 10.7326/0003-4819-119-2-199307150-00005 – volume-title: Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs year: 1996 ident: CIT0015 contributor: fullname: Salmon J – ident: CIT0036 doi: 10.1056/NEJM198611133152005 – ident: CIT0038 doi: 10.1016/S0360-3016(99)00276-X – ident: CIT0032 doi: 10.1056/NEJM198811033191810 – volume: 7 start-page: 272 issue: 4 year: 2001 ident: CIT0019 publication-title: J. Manag. Care Pharm. doi: 10.18553/jmcp.2001.7.4.272 contributor: fullname: Sullivan S. – volume: 15 start-page: 1154 year: 1993 ident: CIT0016 publication-title: Clinical Therapeutics contributor: fullname: Langley P – volume: 31 start-page: 67 issue: 1 year: 1995 ident: CIT0020 publication-title: Psychopharmacol. Bull. contributor: fullname: Data J.L. – volume-title: Essentials of Managed Health Care year: 1999 ident: CIT0029 contributor: fullname: Kongstvedt P – year: 2002 ident: CIT0025 publication-title: J. Pharm. Mark Manage contributor: fullname: Lin S. – ident: CIT0006 doi: 10.1287/mnsc.15.5.215 – volume-title: Medical Innovation: a Diffusion Study year: 1966 ident: CIT0028 contributor: fullname: Coleman J.S. – ident: CIT0037 doi: 10.1038/scientificamerican0482-120 – year: 2002 ident: CIT0010 publication-title: Wall Street Journal contributor: fullname: Bennett J – ident: CIT0041 doi: 10.1080/02791072.1991.10471602 – volume: 11 start-page: 46 issue: 3 year: 1991 ident: CIT0007 publication-title: J. Health Care Mark. contributor: fullname: Williams J.R. – ident: CIT0011 doi: 10.1056/NEJMsa012075 – volume: 1 start-page: 37 year: 1997 ident: CIT0023 publication-title: American Medical News contributor: fullname: Borzo G – volume: 14 start-page: 161 issue: 3 year: 1999 ident: CIT0039 publication-title: J. Cancer Educ. contributor: fullname: Thompson A.R. – volume-title: Essays in the Economics of Health and Medical Care year: 1972 ident: CIT0001 contributor: fullname: Fuchs V – ident: CIT0008 doi: 10.1016/0002-9343(82)90911-1 – ident: CIT0034 – year: 2002 ident: CIT0009 publication-title: Wall Street Journal contributor: fullname: Martinez B – year: 2002 ident: CIT0012 publication-title: Wall Street Journal contributor: fullname: Hensley S – year: 2002 ident: CIT0003 publication-title: New York Times contributor: fullname: Freudenheim M – volume: 51 start-page: 2593 year: 1994 ident: CIT0021 publication-title: Am. J. Hosp. Pharm. contributor: fullname: Johnson J. |
SSID | ssj0002676 |
Score | 1.548662 |
Snippet | ABSTRACT
Little documentation exists in the scientific literature on the introduction of new technologies in health care, especially for pharmaceuticals. Few... Little documentation exists in the scientific literature on the introduction of new technologies in health care, especially for pharmaceuticals. Few adequate... |
SourceID | crossref informaworld informahealthcare |
SourceType | Aggregation Database Publisher |
StartPage | 397 |
Title | INFLUENCES ON THE ADOPTION OF NEW PHARMACEUTICAL TECHNOLOGIES: THE EXAMPLE OF THE FENTANYL PATCH |
URI | https://www.tandfonline.com/doi/abs/10.1081/CRP-120016436 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbptAFB25zqabKn2pSR-aReUNwYVhYEx3xAG5ro1RjBVnRYeXumidyLEVpX_Qv-5lhpcTV2q6GQyaAcE9ntc991yEPpKYM57mAzW2NKZSwhPVjg1NheEg0w0ex1ZaeHSnvjVa0PHSXHY6v1uspe0m7ie_9saV_I9V4RrYtYiSfYRl65vCBfgN9oUSLAzlP9n4i-9NFsUe0VyZ-YK845zNApFHZ-YpvnuhBCPnfOoM3UUodA9CdzjyRf4Ddy421qGJu3SmwcSt6D-e64eOfzlRAics_UiVkEEVRFkKBMmYuLVMZl-46vmud2jOf_yUPv1xX7koKMEN_UcqF8xvt-qYN4794ZrfVmR7QT8r4t-Vy_7O1kSzhK1CqRZfW-SkonvVLE2FVbHs0rKqyyUqMWWcdN0n2y3s0VYHa0g2bzlWU0nBfjAMwDynkBc-D1SdCBEx457cdr3-gZoR1Ivqek_QAWG2SbvowDk9O_XqYZ1YIlNh_QqlYCvc4NPOg3YmOIel_O33msx3TxK3NZkJD9GzchWCHQmp56iTrV6gXiBlzO9OcNhE5d2c4B4OGoHzu5foW4M7PPMxoAZXuMMzDwPu8C7ucBt3n0WDEnVF_eK0Qh0WqHuFFp4LR7XM1KEmhkE2qp3qsZklxiCjMChAmRg5y-wkHyQWz0me6FzjJklzznOWZ4yzPKaUwdLZIjbLufEadVdXq-wNwpaeMEoI5zE1aEZsTlIT2jOdJkyztfQI9arPG11LQZZoryGPkPbg40fln_fmb030tm2ijdg0y2WGm8jY2-b48Y95i56KnEJiI-8d6m7W2-w9TG038YcSdH8ALZCTiA |
link.rule.ids | 315,786,790,4043,27954,27955,27956 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=INFLUENCES+ON+THE+ADOPTION+OF+NEW+PHARMACEUTICAL+TECHNOLOGIES%3A+THE+EXAMPLE+OF+THE+FENTANYL+PATCH&rft.jtitle=Clinical+research+and+regulatory+affairs&rft.au=Salmon%2C+J.+Warren&rft.au=Lin%2C+Swu-Jane&rft.au=Crawford%2C+Stephanie+Y.&rft.date=2002&rft.pub=Informa+UK+Ltd&rft.issn=1060-1333&rft.eissn=1532-2521&rft.volume=19&rft.issue=4&rft.spage=397&rft.epage=412&rft_id=info:doi/10.1081%2FCRP-120016436&rft.externalDocID=10_1081_CRP_120016436 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1060-1333&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1060-1333&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1060-1333&client=summon |